CRISPR-Cas9 (clustered, regularly interspaced, short palindromic repeats with CRISPR-associated protein 9) is a powerful, versatile, and cost-effective molecular research tool that can be used for genetic engineering purposes and beyond, which is especially suited for non-model organisms. Effective delivery of this system, however, remains a challenge for in vivo genetic manipulation of specific tissues, in adult indivuduals, and in particular for reaching targets in the brain for genome editing. We designed a new CRISPR-Cas9 plasmid that was inserted into a baculovirus vector to knock down the octopamine beta subtype 2 receptor (AmOctβ2R), a transmembrane protein found in the mushroom body neurons of the honey bee (Apis mellifera) brain, to determine if octopamine plays a role in appetite regulation. Starting three days post-treatment, we confirmed gene editing of AmOctβ2R using Sanger sequencing, expression of the CRISPR-Cas9 system with live cell imaging, FACs analysis, and confocal imaging showing a widespread expression of the CRISPR-Cas9 system throughout the honey bee brain, in vitro and in vivo knockdown of AmOctβ2R. We demonstrated appetite suppression in starved forager bees. Taken together, our findings suggest that we successfully delivered the CRISPR-Cas9 system and knocked down AmOctB2R in neuronal cells of the honey bee brain that were previously inaccessible due to the blood-brain barrier and lack of infectivity of viral vectors. The relatively newly characterized AmOctβ2R can now be assigned a functional role related to appetite regulation. Other gene editing targets are now possible using the baculovirus vector containing the CRISPR-Cas9 system.